BRIEF ANTIDEPRESSANT OVERVIEW. Casey Gallimore, Pharm.D., M.S.

Size: px
Start display at page:

Download "BRIEF ANTIDEPRESSANT OVERVIEW. Casey Gallimore, Pharm.D., M.S."

Transcription

1 BRIEF ANTIDEPRESSANT OVERVIEW Casey Gallimore, Pharm.D., M.S.

2 Antidepressant Medication Classes First Generation Tricyclic Antidepressants (TCAs) Monoamine Oxidase Inhibitors (MAOIs) Second Generation Selective Serotonin Reuptake Inhibitors (SSRIs) Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs) Other

3 First Generation Antidepressants

4 Tricyclic Antidepressants (TCAs) Tertiary Amines Imipramine (Tofranil ) Amitriptyline (Elavil ) Demethylated Secondary Amines Desipramine (Norpramin ) Nortriptyline (Pamelor ) Clomipramine (Anafranil ) Doxepin (Silenor )

5 Mechanism of Action: TCAs Inhibits membrane pump mechanism responsible for the absorption of serotonin (5-HT) and norepinephrine (NE) in serotonergic and adrenergic neurons Block muscarinic M1, histamine H1, and alphaadrenergic receptors Amount of 5-HT and NE effects depends on the compound: Tertiary amines = 5-HT > NE reuptake inhibition Secondary amines = NE > 5-HT reuptake inhibition

6 TCA Adverse Effects Block muscarinic M1, histamine H1, and alpha-adrenergic receptors Cardiovascular arrhythmias, tachycardia, orthostatic hypotension Anticholinergic Sedation Neurologic Effects Weight Gain Dangerous in overdose!!! As Sexual Dysfunction little as 10 times the daily dose can be fatal.

7 Responsible receptors Tertiary Amines Muscarinic Histamine Alphaadrenergic Anticholinergic Drowsiness Weight Gain Hypotension QT prolongation 5-HT2 Sexual Dysfunction Amitriptyline Clomipramine Doxepin Imipramine Triimipramine Secondary Amines Desipramine Nortriptyline Protriptyline Miscellaneous Amoxapine Maprotiline high risk, + moderate risk Adapted from UpToDate : Side Effects of Antidepressants (table)

8 Monoamine Oxidase Inhibitors (MAOIs) Phenelzine (Nardil ) Tranylcypromine (Parnate ) Selegiline (Emsam ) Mechanism of Action Irreversible inhibition of MAO-A & B, resulting in increased levels of 5HT, NE, and dopamine Phenelzine and tranylcypromine are non-selective inhibitors Selegiline inhibits MAO-A & B in the brain but has reduced effects in the gut (dose dependent)

9 MAOI Drug Interactions Inhibited metabolism of various monoamines including 5-HT, NE and tyramine can result in: Serotonin syndrome Concurrent serotonergic medications Hypertensive crisis Ingesting large amounts of tyramine or other vasoactive amines in foods or medications Clinical presentation acute onset of severe headache, nausea, neck stiffness, palpitations, profuse perspiration, and confusion can possibly lead to stroke and death

10 MAOI Drug Interactions Concomitant use contraindicated*: Other antidepressants Buspirone Dextromethorphan Sympathomimetic drugs (amphetamine, cocaine, methylphenidate, epinephrine, phenylephrine, etc) Start SSRI or other antidepressant 14 days after stopping MAOI 5 half life wash out of previous antidepressant before starting MAOI * This does not represent a comprehensive list of contraindications

11 MAOI Food Interactions (Tyramine Containing) Absolute Contraindications Aged cheeses, aged and cured meats, banana peel, sauerkraut, soy sauce, tap beer, marmite Moderate Contraindications red or white wine, bottled or canned beer Unnecessary avocados, bananas, chocolate, fresh and mild cheeses, fresh meat, MSG, peanuts, raspberries, soy milk

12 Second Generation Antidepressants

13 Selective Serotonin Reuptake Inhibitors (SSRIs) Citalopram (Celexa ) Escitalopram (Lexapro ) Fluoxetine (Prozac, Prozac Weekly, Sarafem ) Fluvoxamine (Luvox CR) Paroxetine (Paxil, Paxil CR ) Sertraline (Zoloft ) Vilazodone (Viibryd ) Vortioxetine (Trintellix )

14 Mechanism of Action: SSRIs Decreases the action of the presynaptic 5-HT reuptake pump which increases duration of 5-HT in the synapse and increases postsynaptic 5-HT receptor occupancy In addition, vilazodone is 5-HT 1A receptor partial agonist vortioxetine is 5-HT 1A agonist, 5-HT 1B partial agonist, and antagonist of 5-HT 3, 5-HT 1D and 5-HT 7 receptors

15 Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) Venlafaxine (Effexor, Effexor XR ) Desvenlafaxine (Pristiq ) Duloxetine (Cymbalta ) Levomilnacipran (Fetzima ) Selectively inhibit neuronal reuptake of 5-HT and NE

16 SNRIs Venlafaxine predominately 5-HT effects until dose reaches mg per day Desvenlafaxine O-desmethyl metabolite of venlafaxine via CYP2D6 Duloxetine dual 5-HT and NE action along entire dosing spectrum Also FDA approved for diabetic peripheral neuropathy, fibromyalgia, chronic musculoskeletal pain Levomilnacipran greatest noradrenergic activity in vitro among available SNRIs

17 Norephinephrine Dopamine Reuptake Inhibitors (NDRIs) Bupropion (Wellbutrin, Wellbutrin SR, Wellbutrin XL ) Inhibits neuronal uptake of NE and dopamine Also FDA indication for smoking cessation (Zyban )

18 Other serotonin modulators Mirtazapine (Remeron ) Increases 5-HT and NE release by central presynaptic alpha2- adrenergic antagonist effects Potent antagonist of 5-HT2 and 5-HT3 serotonin receptors and H1 histamine receptors and a moderate peripheral alpha1-adrenergic and muscarinic antagonist Trazodone (Oleptro ) Increases serotonergic neurotransmission Blocks histamine (H1) and alpha1-adrenergic receptors Nefazodone (Serzone ) Antagonist of 5HT-2 receptors and 5-HT reuptake blocking

19 St. John s Wort Herbal product (Hypericum perforatum) Modulates neurotransmitter levels of 5-HT, NE, and dopamine most likely by inhibiting reuptake

20 Shared Adverse Effects Acute GI effects (upset, nausea, vomiting) Dizziness Headache Sedation / Insomnia Anxiety / jitteriness ** usually tolerate out after 1-4 weeks Chronic Sweating Tremor Vivid dreams Increased bleeding risk Hyponatremia Sexual dysfunction Worsening mood / suicide Serotonin syndrome

21 Fluoxetine Sertraline Citalopram & Escitalopram Fluvoxamine Paroxetine Vilazodone (Viibryd) Vortioxetine (Brintellix) -Longest t ½ (self-tapering) -CYP 2D6, 3A4, 2C inhibitor -Diarrhea as adverse effect -Risk of QT prolongation -Few drug-drug interactions -CYP 1A2, 3A4, 2C inhibitor -Often prescribed for OCD -Anticholinergic effects, most sedating, wt gain -Shortest t ½ (withdrawal) -CYP 2D6 inhibitor -SSRI + 5-HT1A receptor partial agonist -Lower risk of sexual dysfunction -SSRI + 5-HT1A agonist, 5-HT1B partial agonist, and antagonist of 5-HT3, 5-HT1D and 5-HT7 receptors -Main ADEs: GI related (nausea, vomiting, constipation)

22 Unique Attributes SNRIs Increased BP and HR (least potential with duloxetine, greatest with venlafaxine) GI effects (upset, N/V, constipation) slow taper, use venlafaxine XR formulation Levomilnacipran (Fetzima ) newest SNRI Bupropion Decreased appetite Restlessness, insomnia (dose earlier in day) Lowered seizure threshold (contraindicated with seizure disorder and eating disorders) Lower risk of sexual dysfunction

23 Unique Attributes Mirtazapine Weight gain Sedation More prominent at lower doses Dry mouth Constipation Lower risk of sexual dysfunction Trazodone Sedation Hypotension Priapism Low incidence of sexual side effects Nefazodone Hepatitis, liver failure 1 per 250,000 to 300,000 patient-years in US Lower risk of sexual dysfunction

24 Place in Therapy

25 First vs Second Generation Antidepressants Equivalent efficacy in treating depression and many anxiety disorders However, second generation agents generally preferred over first generation agents Fewer drug interactions Improved tolerability Greater safety profile

26 FDA-Labeled Indications Antidepressant MDD GAD SAD PD OCD PTSD BPD Citalopram X Escitalopram X X Fluoxetine X X X X Fluvoxamine X Paroxetine X X X X X X Sertraline X X X X X Vilazodone X Vortioxetine X Venlafaxine X X X X Desvenlafaxine X Duloxetine X X Levomilnacipran X Mirtazapine X Trazodone X Nefazodone X Bupropion X MDD=major depressive disorder, GAD=generalized anxiety disorder; SAD=social anxiety disorder, PD=panic disorder, OCD=obsessive compulsive disorder, PTSD=post traumatic stress disorder, BPD=bipolar disorder

27 Thank you for your attention! If you have any questions regarding this presentation feel free to me at

PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES

PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES Table of Contents Print TABLE OF CONTENTS Drug Page Number Anafranil... 2 Asendin... 4 Celexa... 4 Cymbalta... 6 Desyrel... 8 Effexor...10 Elavil...14

More information

Antidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry

Antidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry Antidepressant Medication Strategies We ve Come a Long Way or Have We? Joe Wegmann, PD, LCSW The PharmaTherapist Joe@ThePharmaTherapist.com 504.587.9798 www.pharmatherapist.com Are you receiving our free

More information

Children s Hospital Of Wisconsin

Children s Hospital Of Wisconsin Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,

More information

90 dosage units per 90 days OR. Extended-release Formulations Ultram ER 90 dosage units per 90 days OR

90 dosage units per 90 days OR. Extended-release Formulations Ultram ER 90 dosage units per 90 days OR Pre - PA Allowance 12 years of age or older Quantity Immediate-release Formulation Ultracet 720 dosage units per 90 days OR Ultram 720 dosage units per 90 days Extended-release Formulations Ultram ER 90

More information

OXYCODONE IR (oxycodone)

OXYCODONE IR (oxycodone) RATIONALE FOR INCLUSION IN PA PROGRAM Background Oxycodone hydrochloride, a pure opioid agonist, is used in the treatment of moderate to severe pain (1-2). The precise mechanism of action is unknown; however,

More information

BELBUCA (buprenorphine buccal film)

BELBUCA (buprenorphine buccal film) RATIONALE FOR INCLUSION IN PA PROGRAM Background Belbuca is indicated for the management of chronic pain severe enough to require daily, aroundthe-clock, long-acting opioid treatment for which alternative

More information

Duragesic Patch (fentanyl patch) Prior authorization is not required if prescribed by an oncologist

Duragesic Patch (fentanyl patch) Prior authorization is not required if prescribed by an oncologist Pre - PA Allowance Quantity 30 patches every 90 days Prior-Approval Requirements Prior authorization is not required if prescribed by an oncologist Age 2 years of age or older Diagnosis Patient must have

More information

Xartemis XR (oxycodone / acetaminophen extended release)

Xartemis XR (oxycodone / acetaminophen extended release) RATIONALE FOR INCLUSION IN PA PROGRAM Background Xartemis XR is a combination of oxycodone and acetaminophen in a dosage formulation to deliver both immediate pain relief, in less than an hour, and extended-release

More information

HYSINGLA ER (hydrocodone bitartrate) Prior authorization is not required if prescribed by an oncologist.

HYSINGLA ER (hydrocodone bitartrate) Prior authorization is not required if prescribed by an oncologist. Pre - PA Allowance None Prior authorization is not required if prescribed by an oncologist. Prior-Approval Requirements Age 18 years of age or older Diagnosis Patient must have the following: 1. Pain,

More information

MORPHINE IR DRUG CLASS Morphine IR, Dilaudid IR (hydromorphone), Opana IR (oxymorphone)

MORPHINE IR DRUG CLASS Morphine IR, Dilaudid IR (hydromorphone), Opana IR (oxymorphone) Pre - PA Allowance Tablets & Suppositories Morphine sulfate tablets Morphine sulfate suppositories Oxymorphone tablets Hydromorphone tablets Hydromorphone suppositories 360 tablets per 90 days OR 360 suppositories

More information

Pre - PA Allowance. Prior-Approval Requirements LEVORPHANOL TARTRATE. None

Pre - PA Allowance. Prior-Approval Requirements LEVORPHANOL TARTRATE. None Pre - PA Allowance None Prior-Approval Requirements Prior authorization is not required if prescribed by an oncologist and/or the member has paid pharmacy claims for an oncology medication(s) in the past

More information

RATIONALE FOR INCLUSION IN PA PROGRAM

RATIONALE FOR INCLUSION IN PA PROGRAM RATIONALE FOR INCLUSION IN PA PROGRAM Background Tramadol is a centrally acting synthetic opioid analgesic used to treat moderate to moderately severe chronic pain in adults. Along from analgesia, tramadol

More information

Diagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD

Diagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty

More information

Quick Guide to Common Antidepressants-Adults

Quick Guide to Common Antidepressants-Adults Quick Guide to Common Antidepressants-Adults Medication Therapeutic Range (mg/day) Initial Suggested Serotonin Reuptake Inhibitors (SSRIs) All available as generic FLUOXETINE (Prozac) CITALOPRAM (Celexa

More information

Treating Depression in Adults

Treating Depression in Adults Treating Depression in Adults By Deborah Christensen, Ph.D., M.S.C.P. Depressive Disorders represent a broad and heterogeneous group of commonly diagnosed psychological disorders. The DSM adequately describes

More information

Common Antidepressant Medications for Adults

Common Antidepressant Medications for Adults (and Citalopram (Celexa) Escitalopram (Lexapro) Fluoxetine (Prozac) Fluoxetine Weekly (Prozac Weekly) 20 in AM w/ food (10 mg in elderly or those w/ panic disorder) 20 40 40 (If age >60yo, max 20) 10 10

More information

Primary Care Management of Depression. John Briles, MD, Medical Director October 11, 2017

Primary Care Management of Depression. John Briles, MD, Medical Director October 11, 2017 John Briles, MD, Medical Director October 11, 2017 Molina Healthcare of Michigan uses a HEDIS measure for Antidepressant Medication Management (AMM) to measure how well treating providers (PCPs) appropriately

More information

Anti-Depressant Medications

Anti-Depressant Medications Anti-Depressant Medications A Introduction: This topic may be a little bit underestimated here in Jordan, while in western countries it has more significance. The function of anti-depressants is to change

More information

Psychobiology Handout

Psychobiology Handout Nsg 85A / Psychiatric Page 1 of 7 Psychobiology Handout STRUCTURE AND FUNCTION OF THE BRAIN Psychiatric illness and the treatment of psychiatric illness alter brain functioning. Some examples of this are

More information

RATIONALE FOR INCLUSION IN PA PROGRAM

RATIONALE FOR INCLUSION IN PA PROGRAM RATIONALE FOR INCLUSION IN PA PROGRAM Background hydromorphone (Exalgo, Dilaudid) and oxymorphone (Opana and Opana ER) are Schedule II narcotics prescribed to treat moderate to severe pain. Morphine produces

More information

Presentation is Being Recorded

Presentation is Being Recorded Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please

More information

9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded

9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please

More information

Treatment of Major Depressive Disorder

Treatment of Major Depressive Disorder Treatment of Major Depressive Disorder Sarah Mullowney, MD PGY3 Psychiatry Resident, University of Utah Paula Gibbs, MD Medical Director of 5 West at UUMC Clerkship Director MS III Psychiatric Rotation

More information

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution

More information

3. Atypical antidepressants

3. Atypical antidepressants 3. Atypical antidepressants Bupropion, mirtazapine, nefazodone & trazodone. Mixed group that act at several different sites. Bupropion Acts as a weak dopamine & NE reuptake inhibitor. Has short half-life.

More information

Linda Sobeski Farho, PharmD, BCPS Assistant Professor, Pharmacy Practice UNMC College of Pharmacy Critical Issues in Geriatrics June 24, 2010

Linda Sobeski Farho, PharmD, BCPS Assistant Professor, Pharmacy Practice UNMC College of Pharmacy Critical Issues in Geriatrics June 24, 2010 Pharmacologic Treatment of Depression Linda Sobeski Farho, PharmD, BCPS Assistant Professor, Pharmacy Practice UNMC College of Pharmacy Critical Issues in Geriatrics June 24, 2010 1 Disclosure I have no

More information

TREATMENT OF DEPRESSION IN LATE LIFE. Robert Kohn, MD

TREATMENT OF DEPRESSION IN LATE LIFE. Robert Kohn, MD TREATMENT OF DEPRESSION IN LATE LIFE Robert Kohn, MD WHY TREAT ELDERLY PERSONS Major depression is not a normal part of aging The rates are lower than younger cohorts The prevalence rates are still high

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Antidepressant Agents Page 1 of 14 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Antidepressant Agents Prime Therapeutics will review Prior Authorization requests.

More information

Antidepressants Choosing the Right One

Antidepressants Choosing the Right One Antidepressants Choosing the Right One Dr Lim Boon Leng Consultant Psychiatrist Dr BL Lim Centre For Psychological Wellness #09-09, Gleneagles Medical Centre, 6 Napier Rd, S258499 www.psywellness.com.sg

More information

Depression Pharmacology. PHPP 517 (IT-III) Fall 2011

Depression Pharmacology. PHPP 517 (IT-III) Fall 2011 Depression Pharmacology PHPP 517 (IT-III) Fall 2011 Depression Symptoms of Depression Emotional symptoms Physical symptoms Cognitive symptoms Psychomotor symptoms Depression Pharmacology Loss of brain

More information

RATIONALE FOR INCLUSION IN PA PROGRAM

RATIONALE FOR INCLUSION IN PA PROGRAM RATIONALE FOR INCLUSION IN PA PROGRAM Background Methadone hydrochloride is a long-acting opioid agonist at mu-opioid receptors that is used to manage pain that requires long-term, daily opioid treatment

More information

Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE

Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE Chan-Hyung Kim, MD Severance Mental Health Hospital Institute of Behavioral Science in Medicine Diagnostic Criteria Pyramid Etiologic Pathophysiologic

More information

Treat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused

Treat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused Psychiatric Drugs Psychiatric Drugs Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally or abused Benzodiazepines

More information

Affective or Mood Disorders. Dr. Alia Shatanawi March 12, 2018

Affective or Mood Disorders. Dr. Alia Shatanawi March 12, 2018 Affective or Mood Disorders Dr. Alia Shatanawi March 12, 2018 Affective or Mood Disorders Reactive Depression. Secondary: Medical Neurological Drugs Major (Endogenous) Depression = Unipolar: Depressed

More information

Levorphanol. Levorphanol Tartrate. Description

Levorphanol. Levorphanol Tartrate. Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.59 Subject: Levorphanol Page: 1 of 8 Last Review Date: March 17, 2017 Levorphanol Description Levorphanol

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Antidepressant Agents Page 1 of 14 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Antidepressant Agents Prime Therapeutics will review Prior Authorization requests.

More information

A Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer

A Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.

More information

PSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer

PSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally

More information

Antidepressant Agents Step Therapy and Quantity Limit Program Summary

Antidepressant Agents Step Therapy and Quantity Limit Program Summary Antidepressant Agents Step Therapy and Quantity Limit Program Summary FDA APPROVED INDICATIONS AND DOSAGE 1-20,26,27,30,32-35,37-39,40,41,43 Drug MDD OCD PD GAD SAD PDD PTSD Bulimia Other Diagnos es Dosing

More information

Psychopharmacological Management of Depressive and Anxiety Disorders

Psychopharmacological Management of Depressive and Anxiety Disorders Psychopharmacological Management of Depressive and Anxiety Disorders Waseem Ahmed, M.D Medical Director: Population Health and Dallas County Correctional System Email: waseem.ahmed@phhs.org Tel: 214-653-2927

More information

Prepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D.

Prepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D. Prepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D. Sources: National Institute of Mental Health (NIMH), the National Alliance on Mental Illness (NAMI), and from the American Psychological Association

More information

Depression. There are several forms of depression (depressive disorders). Major depressive disorder and dysthymic disorder are the most common.

Depression. There are several forms of depression (depressive disorders). Major depressive disorder and dysthymic disorder are the most common. Depression Depression is a state of low mood and aversion to activity that can affect a person's thoughts, behavior, feelings and sense of well-being. People with depressed mood can feel sad, anxious,

More information

Butrans (buprenorphine patch) Description. Section: Prescription Drugs Effective Date: October 1, 2017

Butrans (buprenorphine patch) Description. Section: Prescription Drugs Effective Date: October 1, 2017 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Butrans Page: 1 of 9 Last Review Date: September 15, 2017 Butrans (buprenorphine patch) Description

More information

Nucynta IR. Nucynta IR (tapentadol immediate-release) Description

Nucynta IR. Nucynta IR (tapentadol immediate-release) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Nucynta IR Page: 1 of 9 Last Review Date: December 8, 2017 Nucynta IR Description Nucynta IR (tapentadol

More information

ANTI-DEPRESSANT MEDICATIONS

ANTI-DEPRESSANT MEDICATIONS ANTI-DEPRESSANT MEDICATIONS This information is not intended to be a substitute for medical advice. It s purpose is solely informative. If your client or yourself are taking antidepressants, do not change

More information

Belbuca (buprenorphine buccal film) Belbuca (buprenorphine buccal film) Description

Belbuca (buprenorphine buccal film) Belbuca (buprenorphine buccal film) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Belbuca Page: 1 of 9 Last Review Date: September 15, 2017 Belbuca (buprenorphine buccal film)

More information

Levorphanol. Levorphanol Tartrate. Description

Levorphanol. Levorphanol Tartrate. Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.59 Subject: Levorphanol Page: 1 of 8 Last Review Date: March 16, 2018 Levorphanol Description Levorphanol

More information

Antidepressant Pharmacology An Overview

Antidepressant Pharmacology An Overview Figure 1. Antidepressant Pharmacology An Overview Source: NEJM 2005;353:1819-34 Figure 2. 1 Figure 3: Antidepressant Pharmacology pictures: Weak inhibition Bupropion NOTE: CYP enzymes noted are those inhibited

More information

ANTIDEPRESSANTS IN USE IN CLINICAL PRACTICE

ANTIDEPRESSANTS IN USE IN CLINICAL PRACTICE Medicinska naklada - Zagreb, Croatia Conference paper ANTIDEPRESSANTS IN USE IN CLINICAL PRACTICE Mark Agius 1 & Hannah Bonnici 2 1 Clare College, University of Cambridge, Cambridge, UK 2 Hospital Pharmacy

More information

Psychiatry curbside: Answers to a primary care doctor s top mental health questions

Psychiatry curbside: Answers to a primary care doctor s top mental health questions Psychiatry curbside: Answers to a primary care doctor s top mental health questions April 27, 2018 Laurel Ralston, DO Psychiatrist, Taussig Cancer Institute Objectives Review current diagnostic and prescribing

More information

Major Depressive Disorder

Major Depressive Disorder Major Depressive Disorder HEDIS Measures And Clinical Practice Guidelines Jennifer Highley, PMHNP-BC Behavioral Health West Point Healthcare Effectiveness Data and Information Set (HEDIS) Performance measures

More information

Realities of Depression in Primary Care Setting

Realities of Depression in Primary Care Setting Realities of Depression in Primary Care Setting Jaroslava Salman, MD Department of Supportive Care Medicine Division of Psychiatry Click to edit Master Presentation Date August 4 th 2018 Disclosure I have

More information

The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders What are functional GI disorders?

The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders What are functional GI disorders? The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders Christine B. Dalton, PA-C Douglas A. Drossman, MD and Kellie Bunn, PA-C What are functional GI

More information

Duragesic patch. Duragesic patch (fentanyl patch) Description

Duragesic patch. Duragesic patch (fentanyl patch) Description 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.31 Subject: Duragesic patch Page: 1 of 9 Last Review Date: September 15, 2017 Duragesic patch Description Duragesic patch (fentanyl

More information

Demerol (meperidine oral tablet, oral solution), Meperitab (oral tablet)

Demerol (meperidine oral tablet, oral solution), Meperitab (oral tablet) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Meperidine Page: 1 of 7 Last Review Date: September 15, 2017 Meperidine Description Demerol (meperidine

More information

Depression & Anxiety in Adolescents

Depression & Anxiety in Adolescents Depression & Anxiety in Adolescents Objectives 1) Review diagnosis of anxiety and depression in adolescents 2) Provide overview of evidence-based treatment options 3) Increase provider comfort level with

More information

Daniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School

Daniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School Daniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School of Psychology, Fuller Theological Seminary Medical

More information

Belbuca (buprenorphine buccal film) Description. Section: Prescription Drugs Effective Date: October 1, 2016

Belbuca (buprenorphine buccal film) Description. Section: Prescription Drugs Effective Date: October 1, 2016 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Belbuca Page: 1 of 9 Last Review Date: September 15, 2016 Belbuca (buprenorphine buccal film)

More information

Guide to Psychiatric Medications for Children and Adolescents

Guide to Psychiatric Medications for Children and Adolescents Guide to Psychiatric Medications for Children and Adolescents by Glenn S. Hirsch, M.D. The following guide includes most of the medications used to treat child and adolescent mental disorders. It lists

More information

Duragesic patch. Duragesic patch (fentanyl patch) Description

Duragesic patch. Duragesic patch (fentanyl patch) Description 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.31 Section: Prescription Drugs Effective Date: April1, 2017 Subject: Duragesic patch Page: 1 of 10 Last Review Date: March

More information

Hysingla ER. Hysingla ER (hydrocodone bitartrate) Description

Hysingla ER. Hysingla ER (hydrocodone bitartrate) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.38 Subject: Hysingla ER Page: 1 of 9 Last Review Date: September 15, 2017 Hysingla ER Description

More information

Embeda. Embeda (morphine sulfate and naltrexone hydrochloride) Description

Embeda. Embeda (morphine sulfate and naltrexone hydrochloride) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.39 Subject: Embeda Page: 1 of 8 Last Review Date: September 15, 2017 Embeda Description Embeda (morphine

More information

Antidepressant Selection in Primary Care

Antidepressant Selection in Primary Care Antidepressant Selection in Primary Care Rebecca D. Lewis, DO OOA Summer CME Oklahoma City, OK 6 August 2017 Objectives Understand the epidemiology of depression. Recognize factors to help choose antidepressants.

More information

Depression Update. Disclosure. Outline 1/28/2018. David Justice, MD FAPA Director of Behavioral Health Sumter Family Health Center

Depression Update. Disclosure. Outline 1/28/2018. David Justice, MD FAPA Director of Behavioral Health Sumter Family Health Center Depression Update David Justice, MD FAPA Director of Behavioral Health Sumter Family Health Center Disclosure No significant relationships to disclose Outline Overview of depression Standard treatment

More information

Medications and Children Disorders

Medications and Children Disorders Mental Health Comprehensive Services Providing Family Stability and Developing Life Coping Skills Medications and Children Disorders Psychiatric medications can be an effective part of the treatment for

More information

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES Generic Brand HICL GCN Exception/Other BUPROPION HCL WELLBUTRIN, 01653 WELLBUTRIN SR, WELLBUTRIN XL BUPROPION HBR APLENZIN 17050 16996 26198 CITALOPRAM CELEXA 10321 GPID 16344 HYDROBROMIDE DESVENLAFAXINE

More information

Antidepressant Selection in Primary Care

Antidepressant Selection in Primary Care Antidepressant Selection in Primary Care R E B E C C A D. L E W I S, D O O O A S U M M E R C M E B R A N S O N, M O 1 5 A U G U S T 2 0 1 5 Objectives Understand the epidemiology of depression. Recognize

More information

Medications Guide: Public Speaking And Social Anxiety

Medications Guide: Public Speaking And Social Anxiety AnxietyHub.org Dr. Cheryl Mathews Medications Guide: Public Speaking And Social Anxiety Copyright 2016 AnxietyHub Medications Specifically for Public Speaking and Social Anxiety This is not intended to

More information

Professional Practice Minutes September 7 th, 2016

Professional Practice Minutes September 7 th, 2016 Professional Practice Minutes September 7 th, 2016 1. Lung Cancer Screening : Fast Facts Number 1 killer of both men and women in the US (The Global Burden of Cancer 2013) More people die from lung cancer

More information

Morphine IR Hydromorphone IR Oxymorphone IR. Morphine IR, Dilaudid IR (hydromorphone), Opana IR (oxymorphone),

Morphine IR Hydromorphone IR Oxymorphone IR. Morphine IR, Dilaudid IR (hydromorphone), Opana IR (oxymorphone), Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.33 Subject: Morphine IR Drug Class Page: 1 of 11 Last Review Date: December 8, 2017 Morphine IR Hydromorphone

More information

Objectives. Diagnostic Criteria DSM 5. Before we begin I should tell you that. General Diagnostics for Anxiety Disorders 08/02/2014

Objectives. Diagnostic Criteria DSM 5. Before we begin I should tell you that. General Diagnostics for Anxiety Disorders 08/02/2014 Before we begin I should tell you that ANTIDEPRESSANT USE IN ANXIETY, DEPRESSION AND BIPOLAR: HELPFUL OR HARMFUL? Rania Kattura, PharmD, MS, BCPP Clinical Assistant Professor University of Texas at Austin

More information

Change Your Brain, Change Your Life. The Breakthrough Program for Conquering Anxiety, Depression, Obsessiveness, Anger, and Impulsiveness

Change Your Brain, Change Your Life. The Breakthrough Program for Conquering Anxiety, Depression, Obsessiveness, Anger, and Impulsiveness Change Your Brain, Change Your Life The Breakthrough Program for Conquering Anxiety, Depression, Obsessiveness, Anger, and Impulsiveness Daniel G Amen Three Rivers Press New York Appendix Medication 1.

More information

Duragesic patch. Duragesic patch (fentanyl patch) Description. Section: Prescription Drugs Effective Date: January 1, 2019

Duragesic patch. Duragesic patch (fentanyl patch) Description. Section: Prescription Drugs Effective Date: January 1, 2019 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Duragesic patch Page: 1 of 9 Last Review Date: November 30, 2018 Duragesic patch Description Duragesic patch (fentanyl

More information

MAJOR DEPRESSION CLINICAL PRACTICE GUIDELINE

MAJOR DEPRESSION CLINICAL PRACTICE GUIDELINE MAJOR DEPRESSION CLINICAL PRACTICE GUIDELINE Reviewed and Updated by the Behvioral Health Subcommittee 7/20/2017 Topic Purpose Access Assessment 7/2017 Recommendations SummaCare Health Plan bases its Clinical

More information

Treatment of Depression in the Primary Care Office

Treatment of Depression in the Primary Care Office Treatment of Depression in the Primary Care Office Paul E.A. Glaser, MD, PhD Departments of Psychiatry, Pediatrics and Anatomy & Neurobiology University of Kentucky November 5, 2010 Disclosures of Potential

More information

Drug Effectiveness Review Project (DERP) Summary Report on Second-Generation Antidepressants and Antidepressants Literature Scan

Drug Effectiveness Review Project (DERP) Summary Report on Second-Generation Antidepressants and Antidepressants Literature Scan Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Educational Objectives: Outline. Relevant Disclosures. Managing Depression in Primary Care Lake Tahoe, August 2011

Educational Objectives: Outline. Relevant Disclosures. Managing Depression in Primary Care Lake Tahoe, August 2011 Managing Depression in Primary Care Lake Tahoe, August 2011 Descartes Li, M.D. Clinical Professor University of California, San Francisco descartes.li@ucsf.edu Educational Objectives: By the end of the

More information

Schedule FDA & literature based indications

Schedule FDA & literature based indications Psychotropic Medication List Recommended dosages are intended to serve only as a guide for children. Recommended doses are literature based. Clinicians should consult package insert of medications for

More information

Depression and Anxiety. What is Depression? What is Depression? By Christopher Okiishi, MD Spring Not just being sad A syndrome of symptoms

Depression and Anxiety. What is Depression? What is Depression? By Christopher Okiishi, MD Spring Not just being sad A syndrome of symptoms Depression and Anxiety By Christopher Okiishi, MD Spring 2016 What is Depression? Not just being sad A syndrome of symptoms Depressed mood Sleep disturbance Decreased interest in usual activities (anhedonia)

More information

Ruby Williams, M.D. Drugs, Alcohol and Sleep February 24, 2018

Ruby Williams, M.D. Drugs, Alcohol and Sleep February 24, 2018 Ruby Williams, M.D. Drugs, Alcohol and Sleep February 24, 2018 Objectives Describe pharmacology of commonly prescribed drugs for stimulants and hypnotics Brief review of common drugs that affect sleep

More information

Depression: A Darker Shade of Blue. CareOregon Pharmacy

Depression: A Darker Shade of Blue. CareOregon Pharmacy Depression: A Darker Shade of Blue CareOregon Pharmacy Today s Agenda Welcome and Introduction 8:00 Clinical & In Real Life Aspects 8:05 Break 9:15 Medication Review 9:30 Questions 10:30 Closing 10:55

More information

Psychotropic Medications Archana Jhawar, PharmD, BCPP Clinical Faculty of UIC Pharmacy Practice Clinical Psychiatric Pharmacist Jesse Brown VA

Psychotropic Medications Archana Jhawar, PharmD, BCPP Clinical Faculty of UIC Pharmacy Practice Clinical Psychiatric Pharmacist Jesse Brown VA Psychotropic Medications Archana Jhawar, PharmD, BCPP Clinical Faculty of UIC Pharmacy Practice Clinical Psychiatric Pharmacist Jesse Brown VA Goals of Medications Use least number at lowest dose to get

More information

Before you try another medication, try asking your DNA

Before you try another medication, try asking your DNA Before you try another medication, try asking your DNA It s not you, it s your genetics If you re having trouble finding a medication that works for you, don t give up hope. Here s the thing we all respond

More information

Targiniq ER (oxycodone/naloxone extended-release), Troxyca ER (oxycodone /naltrexone extended-release)

Targiniq ER (oxycodone/naloxone extended-release), Troxyca ER (oxycodone /naltrexone extended-release) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.44 Subject: Oxycodone Naloxone Page: 1 of 9 Last Review Date: December 2, 2016 Oxycodone Naloxone

More information

Management of SSRI Induced Sexual Dysfunction. Serotonin Reuptake Inhibitors*

Management of SSRI Induced Sexual Dysfunction. Serotonin Reuptake Inhibitors* Management of SSRI Induced Sexual Dysfunction John J. Miller, M.D. Medical Director, Center for Health and WellBeing Exeter, NH Serotonin Reuptake Inhibitors* fluoxetine clomipramine sertraline paroxetine

More information

Oxycodone. Oxycodone IR, Oxycodone ER, OxyContin, Xtampza ER. Description

Oxycodone. Oxycodone IR, Oxycodone ER, OxyContin, Xtampza ER. Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Oxycodone Page: 1 of 11 Last Review Date: March 17, 2017 Oxycodone Description Oxycodone IR, Oxycodone

More information

Review of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)

Review of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Review of Psychotrophic Medications (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Common Psychiatric Disorders *Schizophrenia *Depression *Bipolar Disorder

More information

Oxycodone. Oxycodone IR, Oxycodone ER, OxyContin, Xtampza ER. Description

Oxycodone. Oxycodone IR, Oxycodone ER, OxyContin, Xtampza ER. Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Oxycodone Page: 1 of 10 Last Review Date: September 15, 2016 Oxycodone Description Oxycodone IR,

More information

Drugs for Emotional and Mood Disorders Chapter 16

Drugs for Emotional and Mood Disorders Chapter 16 Drugs for Emotional and Mood Disorders Chapter 16 NCLEX-RN Review Question 1 Choices Please note Question #1 at the end of Ch 16 pg 202 & Key pg 805 answer is #4 1. Psychomotor symptoms 2. Tachycardia,

More information

Guidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

Guidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive

More information

SUTTER PHYSICIANS ALLIANCE (SPA) 2800 L Street, 7 th Floor Sacramento, CA 95816

SUTTER PHYSICIANS ALLIANCE (SPA) 2800 L Street, 7 th Floor Sacramento, CA 95816 SUTTER PHYSICIANS ALLIANCE (SPA) 2800 L Street, 7 th Floor Sacramento, CA 95816 SPA PCP Treatment & Referral Guideline Managing Depression in Older Adults Developed March 1, 2003 Revised September 21,

More information

Drugs Used in Mood Disorders

Drugs Used in Mood Disorders 33 Drugs Used in Mood Disorders Herbert E. Ward and Albert J. Azzaro DRUG LIST GENERIC NAME PAGE GENERIC NAME PAGE Amitriptyline 389 Amoxapine 389 Bupropion 388 Carbamazepine 395 Citalopram 388 Clomipramine

More information

Monoamine oxidase inhibitors (MAOIs) have wellestablished

Monoamine oxidase inhibitors (MAOIs) have wellestablished SECOND OF 2 PARTS A concise guide to monoamine oxidase inhibitors: How to avoid drug Use these strategies to maximize efficacy and minimize adverse effects when prescribing an MAOI Jonathan M. Meyer, MD

More information

USF Health Psychiatry Clinic. New Patient Questionnaire Adult

USF Health Psychiatry Clinic. New Patient Questionnaire Adult USF Health Psychiatry Clinic New Patient Questionnaire Adult Please mail or fax the completed forms to the address/fax number on the bottom of this page. Completed forms must be received five (5) days

More information

Steps for Initiating Electroconvulsive Therapy Treatment

Steps for Initiating Electroconvulsive Therapy Treatment Steps for Initiating Electroconvulsive Therapy Treatment PSYCHIATRISTS CAN REFER PATIENTS FOR ECT TREATMENT AT EL CAMINO HOSPITAL BY CALLING THE ECT NURSE COORDINATOR AT 650-962-5795. Once the referral

More information

Bupropion HCl, bupropion hydrobromide Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, Forfivo XL

Bupropion HCl, bupropion hydrobromide Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, Forfivo XL Bupropion Generic names Available brands Available strengths and formulations Available in generic Bupropion HCl, bupropion hydrobromide Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, Forfivo XL 75-mg

More information

Objectives: Lifetime prevalence. Neurotransmitters of interest

Objectives: Lifetime prevalence. Neurotransmitters of interest Kelly Kll M. Rock, DNP, CRNP 11/5/11 Objectives: Identify lifetime prevalence of depressive and anxious disorders. Recognize the social and economic burden of depressive and anxious disorders. Understand

More information

MEDICATION GUIDE PARNATE

MEDICATION GUIDE PARNATE MEDICATION GUIDE PARNATE (PAR-nate) (tranylcypromine) tablets What is the most important information I should know about PARNATE? PARNATE can cause serious side effects including: Increase in suicidal

More information

Introduction to Drug Treatment

Introduction to Drug Treatment Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical

More information

Anxiety Disorders.

Anxiety Disorders. Anxiety Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner

More information